Friday, April 29, 2022
New
Personal Consumption Expenditure (PCE)
index data for the month of March has hit the tape. It’s one of the prime inflation prints informing Fed decisions on monetary policy — the next of which comes just next week. Headline PCE last month came in at +1.4%, ahead of the +0.6% initially reported for February.
Year over year PCE managed to hit a 40-year high: +6.6%, above the originally reported +6.4% for February. Stripping out volatile food and energy products, the “core” read on March PCE came in at +5.2% — a tad lower than the +5.3% expected and the +5.4% initially reported the previous month. This illustrates that inflation was clear and present in March, but a large chunk of it was due to food and energy prices.
Real Personal Spending reached +0.2%, swinging to a positive from -0.1% expected and -0.4% in February. As we saw in the initial read on Q1 GDP earlier this week, the consumer appears to be doing his/her part in keeping the economy strong. Clearly, ratcheting down energy costs — which subsequently affect food costs due to deliveries, etc. — would go a long way toward staunching inflation. A 50 basis-point interest rate hike next week from the Fed will also play a part in this.
Exxon Mobil
XOM
missed estimates on its Q1 earnings this morning, with $2.07 per share coming up short of the $2.25 expected in the Zacks consensus. Much of this has to do with a -$3.4 billion write-off in doing its part to boycott Russian oil. Revenues in the quarter beat estimates by +1.8% to $90.5 billion, and is miles ahead of the year-ago $59.15 billion in revenues. Shares are flat on the news; the stock is +42% year to date.
For more on XOM’s earnings, click here.
Colgate-Palmolive
CL
posted only its second earnings miss in the past five years — though three of the previous four quarters just came in-line with expectations — with 74 cents per share shy of the 80 cents anticipated. Sales in the quarter of $4.4 billion were slightly shy of expectations, but slightly above the year-ago tally. Shares are down -5% on the miss, adding to the -5% year to date for the Consumer Staples giant.
For more on CL’s earnings, click here.
Bristol Myers-Squibb
BMY
took out estimates on both top and bottom lines for the third time in the past four quarters: earnings of $1.92 per share easily surpassed the $1.74 expected, on $11.65 billion in revenues, which topped estimates by +3.5%. However, reduced earnings estimates for the Big Pharma company for the full year are taking down shares -5% ahead of the opening bell.
For more on BMY’s earnings, click here.
Questions or comments about this article and/or its author? Click here>>
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers “Most Likely for Early Price Pops.”
Since 1988, the full list has beaten the market more than 2X over with an average gain of +25.4% per year. So be sure to give these hand-picked 7 your immediate attention.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
